1.0Bionovishttps://bionovis.com.br/en/universotranslucidohttps://bionovis.com.br/en/author/universotranslucido/rich600338<blockquote class="wp-embedded-content" data-secret="y4YBvi06QG"><a href="https://bionovis.com.br/en/medicines/nivolumab/">Nivolumab</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://bionovis.com.br/en/medicines/nivolumab/embed/#?secret=y4YBvi06QG" width="600" height="338" title="“Nivolumab” — Bionovis" data-secret="y4YBvi06QG" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://bionovis.com.br/wp-includes/js/wp-embed.min.js </script> Nivolumab Anti-PD-1 monoclonal antibody indicated for the treatment of cancer. Nivolumab Active Ingredient: Nivolumab Indications for Nivolumab: Advanced Melanoma (Non-surgical and Metastatic)Nivolumab as monotherapy (on its own) or in combination with ipilimumab isindicated for the treatment of advanced melanoma(a type of skin cancer)that is unresectable (cannot be treated with surgery) or metastatic (has spread). Specifications […]